A novel benzopyran-fused molecular framework 7ai was discovered as a specific inhibitor of RANKL-induced osteoclastogenesis using a cell-based TRAP activity assay from drug-like small-molecule libraries constructed by diversity-oriented synthesis. Its inhibitory activity was confirmed by in vitro evaluations including specific inhibition of RANKL-induced ERK phosphorylation and NF-kappa B transcriptional activation. 7ai can serve as a specific small-molecule modulator for mechanistic studies of RANKL-induced osteoclast differentiation as well as a potential lead for the development of antiresorptive drugs.
US4391815A
申请人:——
公开号:US4391815A
公开(公告)日:1983-07-05
US4758677A
申请人:——
公开号:US4758677A
公开(公告)日:1988-07-19
[EN] NOVEL BENZOPYRAN COMPOUNDS AND PROCESS FOR THEIR PREPARATION AND USE<br/>[FR] DERIVES DE CHROMANE EN TANT QU'AGONISTES DU RECEPTEUR BETA 3 ADRENERGIQUE
申请人:GLENMARK PHARMACEUTICALS LTD
公开号:WO2003014113A1
公开(公告)日:2003-02-20
Novel benzopyran compounds that are useful as beta 3-adrenergic receptor agonists, pharmaceutical compositions containing these compounds, and processes for their preparation and use.